A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced stage solid cancers – A California Cancer Consortium Study

BACKGROUND: 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) is a novel small molecule ribonucleotide reductase inhibitor. This study was designed to estimate the maximum-tolerated dose (MTD) and oral bioavailability of 3-AP in patients with advanced stage solid tumors. METHODS: Twenty pati...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Chao, Joseph, Synold, Timothy W., Morgan, Robert J., Kunos, Charles, Longmate, Jeff, Lenz, Heinz-Josef, Lim, Dean, Shibata, Stephen, Chung, Vincent, Stoller, Ronald G., Belani, Chandra P., Gandara, David R., McNamara, Mark, Gitlitz, Barbara J., Lau, Derick H., Ramalingam, Suresh S., Davies, Angela, Espinoza-Delgado, Igor, Newman, Edward M., Yen, Yun
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3288125/
https://ncbi.nlm.nih.gov/pubmed/22105720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-011-1779-5
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares